LBPO.CL04 · 临床研究 · Late-Breaking
Late-Breaking Research: Clinical Research 4
-
LB412 · PDF 免疫重编程:胃癌中的个体化T细胞策略 Reprogramming immunity: Personalized T cell approaches in gastric cancer Giulia Milardi, Andrea Pansa, Fabio Marchianò, Silvia Erratico, Miriam Cieri, Giovanni Garbarino, Luigi Maria Terracciano, Rita Alfieri, Silvia Basato, Alberto Puccini, Alessandro Repici, Cesare Hassan, Charlotte Ng, Chiara Cattaneo, Carlo Castoro, Salvatore Piscuoglio
-
LB413 · PDF 以外周血作为癌症新抗原和反应性T细胞发现的唯一来源 Peripheral blood as the sole source for cancer neoantigen and reactive T cell discovery Andrea Garcia Garijo, Immaculada Creus-González, Pierre Levy, Ana Belen Moreno-Cárdenas, Maria Lozano-Rabella, Carlos Alberto Fajardo, Ricardo Pujol-Borrell, Albert Marín, Johanna Kusnick, Jared Gartner, Anna Yuste-Estevanez, Alma Calahorro, Jose Fernandez, Rebeca Sanz, Thomas B. K. Watkins, Vladimir Galvao, Eva Muñoz-Couselo, Javier Ros, Elena Elez, Mafalfa Oliveira, Cristina Saura, Irene Braña, Ana Oaknin, Ramon Alemany, Josep Tabernero, Raquel Perez-Lopez, Alexander M. Frankell, Elena Garralda, Rodrigo De Almeida Toledo, Alena Gros
-
LB414 · PDF 肿瘤浸润淋巴细胞疗法(LM103)治疗转移性黑色素瘤的最新临床疗效和转化生物标志物分析 Updated clinical efficacy and translational biomarker analysis of tumor infiltrating lymphocyte therapy (LM103) in metastatic melanoma Chuanliang Cui, Li Zhou, Yan Kong, Xuan Wang, Yue Yang, Jiayong Liu, Zhichao Tan, Zhihong Chi, Lu Si, Bin Lian, Lili Mao, Hui Tian, Yuan Yuan, Yongming Xue, Jun Guo
-
LB415 · PDF 纳米抗体:STING激动剂重编程肿瘤微环境并改善实体瘤的过继细胞疗法 Nanobody:STING agonists reprogram the tumor microenvironment and improve adoptive cell therapy for solid tumors Neil C. Chada, Alexandra E. Lee, Hailey Jane Frank, Dawn K. Oh, Hannah Ki, Alexander J. Kwiatkowski, Karan Arora, John T. Wilson
-
LB416 · PDF 靶向XPO1重编程免疫微环境并使胰腺导管腺癌对免疫检查点阻断敏感 Targeting XPO1 reprograms immune microenvironment and confers sensitivity to immune checkpoint blockade in pancreatic ductal adenocarcinoma Md Hafiz Uddin, Mohammed Najeeb Al Hallack, Misako Nagasaka, Sahar F. Bannoura, Husain Y. Khan, Amro Aboukameel, Fulya K. Alkan, Hilmi K. Alkan, Khalil Choucair, M Wasif Saif, Bin Bao, Ibrahim Azar, Eliza W. Beal, Miguel Tobon, Steve Kim, Amr Mohamed, Gregory Dyson, Rafic Beydoun, Ramzi M. Mohammad, Herbert Chen, Bassel El-Rayes F. El-Rayes, Philip A. Philip, Boris C. Pasche, Hasan Korkaya, Asfar S. Azmi
-
LB417 · PDF 通过治疗性拮抗mSWI/SNF染色质重塑复合物重编程抗肿瘤免疫 Reprogramming anti-tumor immunity through therapeutic antagonism of the mSWI SNF chromatin remodeling complex Fan Yang, Yi Bao, Lanbo Xiao, Yuanyuan Qiao, Weiping Zou, Arul M. Chinnaiyan
-
LB418 · PDF RELATIVITY-104第2部分:程序性死亡配体1(PD-L1)≥1%和非鳞状(NSQ)非小细胞肺癌(NSCLC)亚组的转化分析 RELATIVITY-104 Part 2: translational analyses in the programmed death ligand 1 (PD-L1) ≥ 1% and non-squamous (NSQ) non-small cell lung cancer (NSCLC) subgroup Jaclyn Neely, Annie Yu, Nicolas Girard, Manuel Cobo-Dols, Mauricio Burotto, Luis Paz-Ares, Vamsidhar Velcheti, Martin Reck, Srijata Samanta, Anila Qureshi, Priyanka Kasbekar, Charlie Garnett-Benson
-
LB419 · PDF RELATIVITY-020 A-C部分中nivolumab加relatlimab(NIVO+RELA)在实体瘤中的剂量递增和扩增 Dose escalation and expansion of nivolumab plus relatlimab (NIVO + RELA) in solid tumors in RELATIVITY 020 Parts A-C Paolo A. Ascierto, Carlo Gomez-Roca, Ignacio Melero, Katriina Jalkanen, Rachel E. Sanborn, Juan Martin-Liberal, James Larkin, Rastilav Bahleda, F. Stephen Hodi, Margaret Callahan, Marta Nykas, Giuseppe Curigliano, Sebastian Bauer, Solange Peters, Takekazu Aoyama, Mark Semaan, Sourav Mukherjee, Sonia Dolfi, Satyendra Suryawanshi, Evan Lipson
-
LB420 · PDF SAAL1:一种预测食管鳞状细胞癌免疫治疗耐药的新型生物标志物及克服耐药的治疗靶点 SAAL1: A novel biomarker for predicting and therapeutic target for overcoming immunotherapy resistance in esophageal squamous cell carcinoma Caiyan Fang, Fujin Shi, Zhiyi Zhang, Hong Yang
-
LB421 · PDF 体外光分离置换疗法与全身免疫抑制治疗免疫相关不良事件的比较:前瞻性双臂PRIA研究的最终分析 Extracorporeal photopheresis vs. systemic immunosuppression for treatment of immune-related adverse events: Final analysis of the prospective two-arm PRIA study Lisa Wein, Carolin Ertl, Theresa Ruf, Monika Morak, Ying Wang, Christina Schmitt, Xiomara Garza Vazquez, Valerie Glatzel, Richard David-Rus, Mohammed Mitwalli, Jerome Srour, Pia Schöpf, Dirk Tomsitz, Lars E. French, Lucie Heinzerling
-
LB422 · PDF 共过表达CEACAM6的胰腺导管腺癌中免疫检查点的临床价值 Clinical value of immune checkpoints in pancreatic ductal adenocarcinomaco-overexpressing with CEACAM6 Daruka Mahadevan, Chenbo Sun, Yuliang Chen, Aisha Al-Khinji, Ritu Pandey
-
LB423 · PDF 在同源重组缺陷(HRD)胰腺癌接受PARP-PD-1双重阻断的卓越应答者中激活预存的肿瘤浸润性可扩增(TIE)T细胞克隆型 Invigorating pre-existing tumor-infiltrating expandable (TIE) T cell clonotypes in exceptional responders with dual PARP-PD-1 blockade in homologous recombination deficient (HRD) pancreatic cancer Marc Hilmi, Wilson Mckerrow, Joshua D. Schoenfeld, Shigeaki Umeda, Nuray Tezcan, Catherine O'Connor, Yuval Elhanati, Charlotte Reiche, Martina Milighetti, Mara Sherman, Elias-Ramzey Karnoub, Roshan Sharma, Vincenzo Nasca, Kevin Soares, Zeynep Tarcan, Jerry Melchor, Olca Basturk, Nadeem Riaz, Nicolas Lecomte, Vinod P. Balachandran, Dana Pe’er, Benjamin D. Greenbaum, Christine A. Iacobuzio-Donahue, Eileen M. O'Reilly, Wungki Park
-
LB424 · PDF GZMA+ CD8+ T细胞是BRCA突变乳腺癌对新辅助PARPi联合抗PD-1治疗产生病理完全缓解的基础 GZMA+ CD8+ T cells underlie the pathological complete response of BRCA-mutated breast cancers to neoadjuvant PARPi plus anti-PD-1 therapy Songhan Li, Bo Liu, Fei Xie, Yuan Peng, Shu Wang, Hai Qi
- LB425 LB425 在接受现成型癌症"暗物质"疫苗DPV-001联合抗PD-1±抗GITR治疗的头颈鳞状细胞癌(HNSCC)患者中寻找抗癌免疫的靶点 Search for targets of anti-cancer immunity in patients receiving an off-the-shelf cancer's dark matter vaccine, DPV-001, combined with anti-PD-1 +/- anti-GITR in head and neck squamous cell cancer (HNSCC) Traci Hilton, Ryan Meng, Guo Hui Gan, Tarsem Moudgil, Christopher Paustian, Noah Simons, Venkatesh Rajamanickam, Shawn M. Jensen, Elie Adwani, Sierra J. Smith, Matthew H. Taylor, Olivier Fesneau, Thomas M. Duhen, Irene Shih, Myungkyu Jang, Annie Long, Abigail Staeck, Tijana Jovanovic, Brady Bernard, Christie Tanisha, Noriko Iwamoto, Yuriko Minegishi, Koji Ueda, William L. Redmod, Lessli M. Rushforth, Takashi Shimada, Patrick Rethwisch, Carlo B. Bifulco, Hong-ming Hu, Walter J. Urba, Yoshinobu Koguchi, Marcus A. Couey, Richard B. Bell, Jianguo Huang, Eric Tran, Brian Piening, Rom Leidner, Bernard A. Fox
-
LB426 · PDF 阻断肿瘤内在TGF-beta信号驱动小细胞肺癌超进展 Blockade of tumor-intrinsic TGF-beta signaling drives hyperprogression in small cell lung cancer Anish Thomas, Brett Schroeder, Chirayu Mohindroo, Anna-Lena Meinhardt, Nobuyuki Takahashi, Rajesh Kumar, Yang Zhang, Ajit Kumar Sharma
-
LB427 · PDF 人源化PDX模型揭示调控DLBCL中T细胞治疗反应的药物可逆表观遗传免疫排斥,并通过EPICORE分层器在患者中捕获 Humanized PDX models uncover drug-reversible epigenetic immune exclusion governing T-cell therapy response in DLBCL, captured in patients by EPICORE stratifier Giovanni Medico, Giorgia Zanetti, Giorgio Bertolazzi, Francesco Vallania, Paul Zumbo, Maider Amiama, Doron Betel, Maria Cacciapuoti, Abigail Taylor, Clarisse Kayembe, Sanjay Patel, Arvin Ruiz, Jennifer Ziello, Jason Weirather, Gulpreet Kaur, Luca Cappelli, Luca Paruzzo, Marco Ruella, Zhenyuan Dong, Larry Kwak, Nicolás Di Siervi, Maria Revuelta, Claudio Tripodo, Leandro Cerchietti, Giorgio Inghirami
-
LB428 · PDF 靶向EZH2以克服mCRPC的免疫治疗耐药性,揭示NSD2依赖性肿瘤脆弱性 Targeting EZH2 to overcome immunotherapy resistance in mCRPC unlocks NSD2-dependent tumor vulnerabilities Pilar Salamanca Jiménez, Inés Gonzalez-Vazquez, Roderic Espin, Nadia Garcia, Lidia Franco, MA Pujana, JM Piulats, Alvaro Aytes
-
LB429 · PDF 严重肝转移对实体瘤免疫治疗临床应答的影响 Impact of severe liver metastases on clinical response to immunotherapy in solid tumors Jibran Ahmed, Bettzy Stephen, Evan Kwiatkowski, Marcus R. Anderson, Mohamed H. Derbala, Israa Salih, Lilibeth Castillo, Yali Yang, Serdar A. Gurses, Hao Yan, Joann T. Lim, Albert R. Klekers, Hung Le, Lei Kang, Mingxuan Xu, Harold N. Tan, Stephane Champiat, Tin-Yun Tang, Ecaterina E. Dumbrava, Sarina A. Piha-Paul, Jordi Rodon Ahnert, Apostolia M. Tsimberidou, Timothy A. Yap, Siqing Fu, David S. Hong, Funda Meric-Bernstam, Priya R. Bhosale, Aung Naing